首頁 > 市場調查報告書 > 醫療設備

重症加護治療市場規模、佔有率、成長分析（按藥物類別、應用和地區）- 2025-2032 年產業預測

市場調查報告書

商品編碼

1847127

重症加護治療市場規模、佔有率、成長分析（按藥物類別、應用和地區）- 2025-2032 年產業預測

Critical Care Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (Albumin, Prothrombin Complex Concentrates), By Application (Deep Vein Thrombosis, Pulmonary Embolism (PE)), By Region - Industry Forecast 2025-2032

出版日期: 2025年10月13日 | 出版商:

SkyQuest | 英文 175 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計 2023 年全球重症加護治療市場價值將達到 442 億美元，從 2024 年的 468.5 億美元成長到 2032 年的 746.7 億美元，預測期內（2025-2032 年）的複合年成長率為 6.0%。

全球重症加護治療市場的發展受到敗血症和呼吸衰竭等危及生命的疾病發病率上升以及加護病房治療需求日益成長的驅動。對創新藥物製劑的需求以及人工智慧與臨床決策的整合正在改善治療效果和患者預後。此外，人口老化和ICU入院人數激增也促進了市場成長。然而，該行業也面臨著許多挑戰，包括先進療法的高昂成本限制了低收入地區的患者獲得治療，監管障礙阻礙了產品的普及，以及訓練有素的重症加護專業人員的短缺影響了醫療服務的提供。此外，醫療基礎設施的地區差異進一步阻礙了重症加護治療的公平可及，從而影響了市場擴張。

全球重症加護治療市場促進因素

全球重症加護治療市場受到敗血症、創傷和呼吸衰竭等嚴重疾病帶來的日益嚴峻的醫療保健挑戰的驅動，導致對加護病房治療的需求不斷增加。促成這項需求的關鍵因素包括人口老化、ICU入院人數的增加以及對早期療育重要性的認知的提高。為了滿足患者不斷變化的需求，醫療保健系統正在加強ICU容量並最佳化治療通訊協定。這反映出已開發經濟體和新興經濟體都在朝著改善重症患者管理和資源配置的方向轉變。

限制全球重症加護治療市場的因素

阻礙全球推廣先進重症加護療法的一個主要障礙是這些療法的高成本，尤其是在中低收入國家。醫療保健預算的資金限制嚴重限制了這些可能挽救生命的療法的可及性，並對公平醫療造成了重大障礙。醫療保健成本的差異可能會影響區域市場動態，導致不同地區經濟狀況下的成長軌跡不同。因此，解決這些與成本相關的挑戰對於改善全球重症加護療法的可近性至關重要。

全球重症加護藥物市場趨勢

全球重症加護治療市場正經歷顯著成長，這得益於人工智慧臨床決策支援系統的進步。加護病房中人工智慧的應用正在徹底改變診斷和治療方法，實現預測分析、即時監控和演算法驅動的治療通訊協定。這使得醫療服務提供者能夠更早進行干預，改善患者預後，同時增強患者及其家屬的課責。隨著醫院採用這些創新的人工智慧應用來提高準確性和營運效率，他們對數據驅動臨床系統的依賴將推動下一代重症加護治療的發展，從根本上改變重症醫療服務的模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 按部門分類的公司佔有率分析
- 收益同比比較（2022-2024 年）

主要企業簡介

Johnson & Johnson（USA）
Roche Holding AG（Switzerland）
Merck & Co., Inc.（USA）
Pfizer Inc.（USA）
AbbVie Inc.（USA）
AstraZeneca plc（UK）
Novartis AG（Switzerland）
Bristol Myers Squibb（USA）
Eli Lilly and Company（USA）
Sanofi SA（France）
Novo Nordisk A/S（Denmark）
GSK plc（UK）
Amgen Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
Boehringer Ingelheim（Germany）
Gilead Sciences, Inc.（USA）
Bayer AG（Germany）
Baxter International Inc.（USA）
Grifols, SA（Spain）
Cipla Ltd.（India）

結論和建議

簡介目錄

Product Code: SQMIG35I2449

Global Critical Care Therapeutics Market size was valued at USD 44.2 billion in 2023 and is poised to grow from USD 46.85 billion in 2024 to USD 74.67 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global critical care therapeutics market is driven by the rising incidence of life-threatening conditions such as sepsis and respiratory failure, coupled with an increasing need for intensive care unit therapies. The demand for innovative drug formulations and the integration of artificial intelligence in clinical decision-making are enhancing treatment effectiveness and patient outcomes. Additionally, an aging population and the surge in ICU admissions are contributing to market growth. However, this sector faces challenges, including the high costs of advanced therapeutics limiting access in low-income areas, regulatory hurdles that delay product introductions, and a shortage of trained critical care professionals affecting delivery. Variations in healthcare infrastructure across regions further complicate equal access to critical care interventions, impacting market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Critical Care Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Critical Care Therapeutics Market Segments Analysis

Global Critical Care Therapeutics Market is segmented by Drug Class, Application and region. Based on Drug Class, the market is segmented into Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates, Factor XIII Concentrates and Fibrinogen Concentrates. Based on Application, the market is segmented into Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome, Atrial Fibrillation, Hemodialysis, Coronary Angioplasty and Surgeries. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Critical Care Therapeutics Market

The Global Critical Care Therapeutics market is being propelled by the escalating healthcare challenges posed by critical conditions such as sepsis, trauma, and respiratory failure, resulting in a heightened need for intensive care unit therapies. Key factors contributing to this demand include an aging population, a rise in ICU admissions, and growing awareness surrounding the importance of early intervention. To meet the evolving needs of patients, healthcare systems are enhancing ICU capacities and optimizing treatment protocols, which reflects a broader shift in both developed and emerging economies towards improved critical care management and resource allocation.

Restraints in the Global Critical Care Therapeutics Market

A major obstacle hindering the widespread adoption of advanced critical care therapeutics globally is the prohibitive cost associated with these treatments, especially in low- and middle-income nations. The financial constraints within healthcare budgets significantly restrict access to these potentially lifesaving medications, creating a substantial barrier to equitable care. This disparity in affordability may reshape the regional dynamics of the critical care therapeutics market, resulting in varying growth trajectories based on the economic status of different regions. As a result, addressing these cost-related challenges is crucial for improving access to critical care therapies worldwide.

Market Trends of the Global Critical Care Therapeutics Market

The Global Critical Care Therapeutics market is experiencing significant growth driven by advancements in AI-driven clinical decision support systems. The incorporation of artificial intelligence in intensive care units is revolutionizing diagnostics and treatment methodologies, allowing for predictive analytics, real-time monitoring, and algorithm-driven treatment protocols. This enables healthcare providers to intervene earlier and enhance patient outcomes while fostering accountability to patients and their families. As hospitals adopt these innovative AI applications to achieve precision and operational efficiency, the reliance on data-derived clinical systems is set to propel the development of next-generation critical care therapeutics, fundamentally altering the landscape of critical healthcare delivery.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Critical Care Therapeutics Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Albumin
Prothrombin Complex Concentrates
Antithrombin Concentrates
Factor XIII Concentrates
Fibrinogen Concentrates

Global Critical Care Therapeutics Market Size by Application & CAGR (2025-2032)

Market Overview
Deep Vein Thrombosis
Pulmonary Embolism (PE)
Acute Coronary Syndrome
Atrial Fibrillation
Hemodialysis
Coronary Angioplasty
Surgeries

Global Critical Care Therapeutics Market Size & CAGR (2025-2032)

North America (Drug Class, Application)
- US
- Canada
Europe (Drug Class, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments